Anuradha Kunthur
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Also affiliated: Central Arkansas Veterans Healthcare System (2015–2019); Winrock International (United States) (2026); Lady of Mercy Medical Center (2006); John L. McClellan Memorial Veterans Hospital (2015–2020)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Anuradha Kunthur's research focuses on cancer treatment and pharmacology, with a particular emphasis on understanding treatment outcomes and the tumor microenvironment. Recent publications investigate the impact of immunotherapies like durvalumab and pembrolizumab in gastric cancer, analyzing cardiovascular outcomes through propensity-matched TriNetX data. Kunthur also explores genomic correlates of survival in prostate small cell carcinoma using data from the AACR Project GENIE Database. Further work examines multimodal reprogramming of the tumor microenvironment in hepatocellular carcinoma models through MMR and dual checkpoint blockade. Kunthur has authored 18 publications, with a total of 203 citations and an h-index of 6. Key collaborators include Bahaa Mustafa, Steven R. Post, Martin J. Cannon, and Mulu Z. Tesfay, all from the University of Arkansas for Medical Sciences.
Metrics
- h-index: 6
- Publications: 18
- Citations: 203
Selected Publications
-
Association Between Metabolic Syndrome and Prostate Cancer: A Systematic Review (2026)
-
Cardiovascular outcomes of durvalumab versus pembrolizumab in gastric cancer: A propensity-matched TriNetX analysis. (2026)
-
Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025)
-
Acquired Amegakaryocytic Thrombocytopenia Misdiagnosed as Immune Thrombocytopenia: A Case Report (2020)
-
Survival Outcomes in Stage IV Bladder Cancer Patients Treated with Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine: A Retrospective Analysis in Veteran Patients (2020)
-
Clinical and histological response to combination nivolumab and ipilimumab in metastatic renal cell carcinoma (2020)
-
Pazopanib- and bevacizumab-induced reversible heart failure in a patient with metastatic renal cell carcinoma: A case report (2015)
Collaboration Network
Top Collaborators
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
Similar Researchers
Based on overlapping research topics